Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Intermittent dosing regimens for oral risedronate (once-monthly and once-weekly) were developed for patient convenience. While several studies have reported the anti-fracture efficacy of weekly dosing, few have assessed monthly dosing. The lower efficacy of monthly dosing has been previously suggested. The aim of this study was to compare the anti-fracture efficacy of monthly and weekly dosing. Methods: We obtained information from the Korea National Health Insurance Service database from 2012 to 2017 of Korean women of ≥50 years of age who used weekly or monthly risedronate. We compared the time of occurrence of the first osteoporotic fracture after the first prescription of risedronate. Using a Cox proportional model, we assessed incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for fractures at any site, and the hip, vertebral, and non-vertebral sites between both regimens. Propensity score weighting was used to balance the treatment groups. Results: The study populations were distributed according to dosing frequency (monthly, 27,329; weekly, 47,652). There was no significant difference in the incidence rate of new fractures in any site (IRR, 1.008; 95% CI, 0.963– 1.055; P=0.737), hip (IRR, 0.999; 95% CI, 0.769–1.298; P=0.996), vertebral (IRR, 0.962; 95% CI, 0.890–1.040; P=0.330), or non-vertebral (1.022; 95% CI, 0.968–1.078; P=0.439) sites between monthly and weekly risedronate. Conclusion: The anti-fracture efficacy at any site and the examined individual sites was similar for the monthly and weekly risedronate regimens. Large-scale randomized controlled trials are required for confirmation.
Abstract
Background: Intermittent dosing regimens for oral risedronate (once-monthly and once-weekly) were developed for patient convenience. While several studies have reported the anti-fracture efficacy of weekly dosing, few have assessed monthly dosing. The lower efficacy of monthly dosing has been previously suggested. The aim of this study was to compare the anti-fracture efficacy of monthly and weekly dosing. Methods: We obtained information from the Korea National Health Insurance Service database from 2012 to 2017 of Korean women of ≥50 years of age who used weekly or monthly risedronate. We compared the time of occurrence of the first osteoporotic fracture after the first prescription of risedronate. Using a Cox proportional model, we assessed incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for fractures at any site, and the hip, vertebral, and non-vertebral sites between both regimens. Propensity score weighting was used to balance the treatment groups. Results: The study populations were distributed according to dosing frequency (monthly, 27,329; weekly, 47,652). There was no significant difference in the incidence rate of new fractures in any site (IRR, 1.008; 95% CI, 0.963– 1.055; P=0.737), hip (IRR, 0.999; 95% CI, 0.769–1.298; P=0.996), vertebral (IRR, 0.962; 95% CI, 0.890–1.040; P=0.330), or non-vertebral (1.022; 95% CI, 0.968–1.078; P=0.439) sites between monthly and weekly risedronate. Conclusion: The anti-fracture efficacy at any site and the examined individual sites was similar for the monthly and weekly risedronate regimens. Large-scale randomized controlled trials are required for confirmation.
참고문헌 (30)
- 하용찬, "한국 골다공증의 역학", 대한의사협회지, 59(11), pp.836~841 (2016), 대한의사협회[DOI]
- 박은정, "Prevalence of Osteoporosis in the Korean Population Based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008--2011", Yonsei Medical Journal, 55(4), pp.1049~1057 (2014), 연세대학교의과대학[DOI]
- 하용찬, "Trend in Hip Fracture Incidence and Mortality in Korea: A Prospective Cohort Study from 2002 to 2011", Journal of Korean Medical Science, 30(4), pp.483~488 (2015), 대한의학회
- Bliuc D, "Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women", JAMA, 301, pp.513~521 (2009)
- Ha YC, "Economic burden of osteoporosis in South Korea : claim data of the National Health Insurance Service from 2008 to 2011", Calcif Tissue Int, 101, pp.623~630 (2017)
- McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
- Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy(VERT)Study Group", JAMA, 282, pp.1344~1352 (1999)
- Ste-Marie LG, "Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis : a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study", Clin Ther, 31, pp.272~285 (2009)
- Delmas PD, "Monthly dosing of 75 mg risedronate on 2 consecutive days a month : efficacy and safety results", Osteoporos Int, 19, pp.1039~1045 (2008)
- Racewicz AJ, "Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg : a 6-month pilot study", Curr Med Res Opin, 23, pp.3079~3089 (2007)
- Brown JP, "The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis", Calcif Tissue Int, 71, pp.103~111 (2002)
- McClung MR, "Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis : 2-year data", Osteoporos Int, 24, pp.293~299 (2013)
- McClung MR, "Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years", Osteoporos Int, 24, pp.301~310 (2013)
- Delmas PD, "Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis", Bone, 42, pp.36~42 (2008)
- Soen S, "Efficacy on the risk of vertebral fracture with administration of once-weekly 17. 5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures : a 156-week longitudinal observational study in daily practice", J Bone Miner Metab, 35, pp.419~427 (2017)
- Bonnick S, "Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years", J Clin Endocrinol Metab, 91, pp.2631~2637 (2006)
- Lee DR, "Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis : a nationwide population-based study", Osteoporos Int, 30, pp.659~666 (2019)
- Camacho PM, "American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis : 2016", Endocr Pract, 22(Suppl 4), pp.1~42 (2016)
- Siris ES, "Impact of osteoporosis treatment adherence on fracture rates in North America and Europe", Am J Med, 122(2 Suppl), pp.S3~S13 (2009)
- "Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis", Arthritis Rheum, 44, pp.1496~1503 (2001)
- Austin PC, "Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research", Commun Stat Simul Comput, 38, pp.1228~1234 (2009)
- Nancollas GH, "Novel insights into actions of bisphosphonates on bone : differences in interactions with hydroxyapatite", Bone, 38, pp.617~627 (2006)
- Paggiosi MA, "Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis : the TRIO study", Osteoporos Int, 25, pp.2729~2741 (2014)
- Nakamura T, "Clinical efficacy on fracture risk and safety of 0. 5 mg or 1 mg", month intravenous ibandronate versus 2. 5 mg, Calcif Tissue Int, pp.2013, 93[DOI]
- Nakamura T, "Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis", Osteoporos Int, 26, pp.2685~2693 (2015)
- Nakai K, "The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties", Eur J Drug Metab Pharmacokinet, 41, pp.139~147 (2016)
- Yun Jun Yang, "An Overview of Current Physical Activity Recommendations in Primary Care", Korean Journal of Family Medicine, 40(3), pp.135~142 (2019), 대한가정의학회[DOI]
- Park SM, "Zolpidem use and risk of fractures : a systematic review and meta-analysis", Osteoporos Int, 27, pp.2935~2944 (2016)
- Dong-Hyun Kim, "Association between Body Fat and Bone Mineral Density in Normal-Weight Middle-Aged Koreans", Korean Journal of Family Medicine, 40(2), pp.100~105 (2019), 대한가정의학회[DOI]
- 김지현, "The Association between Fat Mass, Lean Mass and Bone Mineral Density in Premenopausal Women in Korea: A Cross-Sectional Study", Korean Journal of Family Medicine, 39(2), pp.74~84 (2018), 대한가정의학회